Global Antihelminthics Market Size By Type (Benzimidazoles, Abamectin), By Application (Schistosomiasis, Fasciolasis), By Region, And Segment Forecasts, 2023 to 2032

lobal Antihelminthics Market Report Description

The Global Antihelminthics Market was valued at USD 2.1 billion in 2023 and is projected to reach USD 3.7 billion by 2031, growing at a CAGR of 7.1% during the forecast period from 2023 to 2031. The growth of the market is primarily driven by the increasing prevalence of parasitic infections, rising awareness regarding animal and human health, and the expanding demand for veterinary healthcare solutions. Antihelminthics are drugs that are used to treat infections caused by parasitic worms in humans and animals, playing a crucial role in public health and livestock management.

Drivers:

Increasing Prevalence of Parasitic Infections:

The global rise in parasitic infections, particularly in developing regions with poor sanitation and limited access to clean water, is significantly driving the demand for antihelminthic drugs.

Growth in Veterinary Healthcare Expenditure:

Growing awareness regarding animal health, coupled with increasing expenditure on veterinary healthcare, is fostering the adoption of antihelminthic treatments for livestock and companion animals.

Rising Focus on Preventive Healthcare:

Governments and healthcare organizations across the globe are increasingly focusing on preventive healthcare measures, including mass drug administration programs for parasite control, boosting the market growth.

Restraints:

Drug Resistance:

The emergence of drug-resistant helminths due to the overuse and misuse of antihelminthics poses a significant challenge, limiting the efficacy of available treatments.

Stringent Regulatory Approvals:

The development and approval process for antihelminthic drugs is highly regulated, often leading to delays in product launches and market entry.

Opportunity:

Expansion in Emerging Markets:

Emerging economies in Asia-Pacific, Latin America, and Africa offer lucrative opportunities due to the high burden of parasitic infections and increasing healthcare awareness.

Development of Novel Drug Formulations:

Ongoing research and development activities focused on novel drug formulations and combination therapies present growth potential for market players.

Market by System Type Insights:

Based on drug type, the Benzimidazoles segment dominated the market in 2023, attributed to its broad-spectrum activity against a wide range of parasitic worms. The segment is expected to maintain its dominance, driven by high efficacy and affordability.

Market by End-use Insights:

By end-use, the Human segment accounted for the largest market share in 2023. The rising incidence of helminth infections in tropical and subtropical regions and increasing public health initiatives are driving the growth of this segment.

Market by Regional Insights:

Geographically, Asia-Pacific led the global antihelminthics market in 2023, owing to a higher prevalence of parasitic infections and government-led deworming programs. North America and Europe follow, with increasing focus on animal health management and advanced healthcare infrastructure.

Competitive Scenario:

Key players operating in the Global Antihelminthics Market include GlaxoSmithKline plc, Pfizer Inc., Bayer AG, Novartis AG, Sanofi S.A., Johnson & Johnson, Merck & Co., Inc., Cipla Ltd., Sun Pharmaceutical Industries Ltd., and Cadila Pharmaceuticals. These companies are focusing on strategic collaborations, R&D investments, and geographical expansion to strengthen their market presence.

Key Market Developments:

In 2023, GlaxoSmithKline plc launched a new combination therapy for soil-transmitted helminth infections with enhanced efficacy.

Pfizer Inc. partnered with a leading veterinary organization in 2022 to develop innovative animal antihelminthic solutions.

Bayer AG expanded its portfolio in 2021 by acquiring a biotechnology firm specializing in anti-parasitic drug development.

Scope of Work – Global Antihelminthics Market

Report Metric Details

Market Size (2023) USD 2.1 billion

Projected Market Size (2031) USD 3.7 billion

CAGR (2023-2031) 7.1%

Key Segments by Drug Type Benzimidazoles, Imidazothiazoles, Macrocyclic Lactones, Others

Key Segments by End-use Human, Veterinary

Leading Region Asia-Pacific

Key Players GlaxoSmithKline plc, Pfizer Inc., Bayer AG, Novartis AG, Sanofi S.A., Johnson & Johnson, Merck & Co., Inc., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Cadila Pharmaceuticals

FAQs

1. What is the current market size of the Global Antihelminthics Market?

The Global Antihelminthics Market was valued at USD 2.1 billion in 2023.

2. What is the major growth driver of the Global Antihelminthics Market?

The major growth driver is the increasing prevalence of parasitic infections and rising awareness regarding healthcare in humans and animals.

3. Which is the largest region during the forecast period in the Global Antihelminthics Market?

Asia-Pacific is expected to dominate the market during the forecast period due to the high burden of parasitic infections and government deworming initiatives.

4. Which segment accounted for the largest market share in the Global Antihelminthics Market?

The Benzimidazoles segment accounted for the largest market share by drug type in 2023.

5. Who are the key market players in the Global Antihelminthics Market?

Key market players include GlaxoSmithKline plc, Pfizer Inc., Bayer AG, Novartis AG, Sanofi S.A., Johnson & Johnson, Merck & Co., Inc., Cipla Ltd., Sun Pharmaceutical Industries Ltd., and Cadila Pharmaceuticals.

Would you like me to prepare this in a Word document for download?